Article Listing - Shionogi-Viiv Healthcare to start regulatory filing of dolutegravir by year-end
Over 200 novel drugs in development for heart disease and stroke, says PhRMA
13 June 2013
America's biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans - heart disease and stroke, according to a new report and overview released yesterday (June 12) by the Pharmaceutical Research and Manufacturers of America (PhRMA).
NICE final draft guidance on Eli Lilly's Alimta negative
13 June 2013
UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (June 13) issued final draft guidance not recommending US drug major Eli Lilly's Alimta (pemetrexed) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin.
Pfizer in $2.15 billion settlement from Teva and Sun for infringement of Protonix patent
12 June 2013
Global pharma behemoth Pfizer (NYSE: PFE) today (June 12) said it has reached a $2.15 billion settlement reached with Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) and India's Sun Pharmaceutical Industries (SUNP: IN) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix (pantoprazole) in the USA.
American Diabetes Association calls for independent review of incretin-based therapy
12 June 2013
The American Diabetes Association is asking all pharmaceutical companies involved in the development or marketing of incretin-based medications, used to lower blood glucose levels, to make patient-level data on their products available for an independent review that could help settle the question of whether such therapies contribute to the development of pancreatitis or pancreatic cancer.
Amgen and Cytokinetics expand omecamtiv mecarbil accord
12 June 2013
USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic collaboration with Cytokinetics (Nasdaq: CYTK) to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure.
Therapeutic effects of Eisai's lenvatinib in melanoma confirmed
12 June 2013
Japanese drug major Eisai (TYO: 4523) says that the therapeutic effects of lenvatinib, a VEGF receptor tyrosine kinase inhibitor and multi-kinase inhibitor discovered in-house, on melanoma have been confirmed in one of a series of joint development programs being conducted as part of the company's strategic collaboration with Quintiles (NYSE: Q). The finding has provided the basis for the first proof of concept (POC) to be achieved under the partnership.
Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study
12 June 2013
US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of 646 patients comparing the subcutaneous (SC) formulation of Orencia (abatacept) versus AbbVie's (NYSE: ABBV) blockbuster drug Humira (adalimumab), each on a background of MTX, in biologic naive patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism (EULAR) annual congress and highlighted during a congress press conference.
NeuroVive signs deal with Isomerase Therapeutics; receives the first milestone from Sihuan
12 June 2013
Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed a collaboration agreement with the UK's Isomerase Therapeutics to develop the molecules that were recently acquired by the British company from Biotica. In addition, the company's Asian subsidiary has received the first milestone payment from Sihuan Pharmaceutical (HKEx: 0460), the company's collaboration partner in China, under a deal signed last year (The Pharma Letter November 21, 2012).
Abcam in deal with Pfizer to supply compounds to researchers
12 June 2013
UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license agreement with global pharma behemoth Pfizer (NYSE: PFE). Under the terms of the agreement, Abcam's Biochemicals division will supply a range of authentic Pfizer compounds for use as preclinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.
WTO TRIPS resolution excludes pharma from IP extension exemption for least-developed countries
12 June 2013
The Council for TRIPS (Trade-Related Aspects of Intellectual Property Rights) yesterday (June 11) adopted a resolution at the World Trade Organization (WTO) that allows least-developed countries (LDC) an eight year extension on an exemption in implementing intellectual property (IP) rules under the TRIPS Agreement, according to medical humanitarian organization Medecins Sans Frontieres (MSF).
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
